🧠 ARA-290 (Cibinetide): Benefits, Research Dosing & Reconstitution Guide

ARA-290 (also known as Cibinetide) is an exciting research peptide that's gaining attention for its potential to support nerve repair, reduce inflammation, and promote tissue healing—without stimulating red blood cell production like erythropoietin (EPO).

Instead, ARA-290 activates the body's Innate Repair Receptor (IRR), which is involved in repairing damaged tissues and calming inflammation.

✨ Potential Research Benefits

Current research suggests ARA-290 may help support:

🧠 Nerve regeneration

🔥 Reduced neuroinflammation

⚡ Relief from neuropathic (nerve) pain

🦶 Improved symptoms of small fiber and diabetic neuropathy

🩹 Tissue healing and repair

❤️ Reduced inflammatory signaling throughout the body

📈 Potential improvements in metabolic health markers (observed in some studies)

One of the biggest advantages is that, unlike EPO, ARA-290 has not been shown to increase red blood cell counts or hematocrit, making it unique among peptides derived from erythropoietin.

💉 Research Dosing

There is currently no FDA-approved dosing protocol, but published human studies have commonly used:

✅ 4 mg daily

Subcutaneous injection
28 consecutive days

Other research has evaluated:

• 1 mg daily

• 4 mg daily

• 8 mg daily

Interestingly, studies found 4 mg daily produced similar benefits to 8 mg daily, suggesting higher doses may not provide additional advantages.

Some research communities also explore protocols such as:

• 2 mg twice weekly

• 2–4 mg every other day

These are community protocols and are not established clinical recommendations.

🧪 Reconstitution with PBS

ARA-290 is commonly reconstituted with sterile Phosphate Buffered Saline (PBS) because it tends to dissolve more readily than with bacteriostatic water.

Example: 10 mg vial

➜ Add 1 mL PBS

Final concentration:

10 mg/mL

✔️ 1 mg = 10 units

✔️ 2 mg = 20 units

✔️ 4 mg = 40 units

❄️ Storage

• Refrigerate after reconstitution (36–46°F / 2–8°C)

• Protect from light

• Gently swirl to dissolve—avoid vigorous shaking

• As with most peptides, use within the recommended storage period after reconstitution

📚 Areas Being Studied

Researchers are investigating ARA-290 for:

✅ Small fiber neuropathy

✅ Diabetic neuropathy

✅ Nerve injuries

✅ Chronic inflammation

✅ Tissue repair and regeneration

While the research is promising, it's important to remember that ARA-290 remains an investigational peptide. More studies are needed to fully understand its long-term safety and effectiveness across different conditions.

Have you been researching ARA-290 or considering adding it to your research protocol? I'd love to hear your thoughts and questions below! 👇

5 comments

🧠 ARA-290 (Cibinetide): Benefits, Research Dosing & Reconstitution Guide